Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Bendroflumethiazide

FDA-approved product (tablet, oral), marketed as Naturetin-10, Naturetin-2.5, Naturetin-5.

Registered studies
9
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Bendroflumethiazide
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cardiovascular disease
  • Hypertension

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Thiazides, plain
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA37.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli29.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae16.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis68.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

9registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Bendroflumethiazide in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.4 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-9.0 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.7 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.7 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Bendroflumethiazide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Mechanisms of Diuretic Resistance in Heart Failure, Aim 3

    NCT06209359 · start 2024-07-24

    Registered record
    Registry ID
    NCT06209359
    Conditions
    Heart Failure; Diuretic Resistance
    Interventions
    Ammonium Chloride; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Recruiting
    Start
    2024-07-24
    Completion
    2029-03-01
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeart Failure; Diuretic Resistance
    InterventionAmmonium Chloride; Placebo
    PhasePhase 1
    Registry statusRecruiting

  • Mechanisms of Diuretic Resistance in Heart Failure, Aim 2

    NCT05753059 · start 2023-08-10

    Registered record
    Registry ID
    NCT05753059
    Conditions
    Heart Failure
    Interventions
    Placebo; Amiloride; Bendroflumethiazide
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Recruiting
    Start
    2023-08-10
    Completion
    2028-06-01
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeart Failure
    InterventionPlacebo; Amiloride; Bendroflumethiazide
    PhasePhase 1
    Registry statusRecruiting

  • Coronavirus (COVID-19) ACEi/ARB Investigation

    NCT04330300 · start 2020-04-30

    Registered record
    Registry ID
    NCT04330300
    Conditions
    Hypertension; COVID-19
    Interventions
    Thiazide or Thiazide-like diuretics; Calcium Channel Blockers; ACE inhibitor; Angiotensin receptor blocker
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Suspended
    Start
    2020-04-30
    Completion
    2021-12-01
    Enrolment
    2,414

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension; COVID-19
    InterventionThiazide or Thiazide-like diuretics; Calcium Channel Blockers; ACE inhibitor; Angiotensin receptor blocker
    PhasePhase 4
    Registry statusSuspended

  • ACEI or ARB and COVID-19 Severity and Mortality in US Veterans

    NCT04467931 · start 2020-01-19

    Registered record
    Registry ID
    NCT04467931
    Conditions
    Hypertension; COVID
    Interventions
    ACEI/ARB; Non-ACEI/ARB; ACEI; ARB
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2020-01-19
    Completion
    2020-12-31
    Enrolment
    22,213

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension; COVID
    InterventionACEI/ARB; Non-ACEI/ARB; ACEI; ARB
    PhaseNot recorded
    Registry statusCompleted

  • Double Blind Crossover Comparison of Diuretics in the Young

    NCT00429897 · start 2006-08

    Registered record
    Registry ID
    NCT00429897
    Conditions
    Low-Renin Hypertension
    Interventions
    Bendroflumethiazide 2.5mg - 5mg; Amiloride 20-40mg; Spironolactone 50-100mg; Frusemide 20-40mg; Bendroflumethiazide 1.25-2.5mg/ Amiloride 10-20mg combined
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2006-08
    Completion
    2007-07
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLow-Renin Hypertension
    InterventionBendroflumethiazide 2.5mg - 5mg; Amiloride 20-40mg; Spironolactone 50-100mg; Frusemide 20-40mg +1 more
    PhaseNot applicable
    Registry statusUnknown

  • Fed Study of Nadolol/Bendroflumethiazide Tablets 80 mg/5 mg and Corzide® Tablets 80 mg/5 mg

    NCT00648297 · start 2006-08

    Registered record
    Registry ID
    NCT00648297
    Conditions
    Healthy
    Interventions
    Nadolol/Bendroflumethiazide Tablets 80 mg/5 mg; Corzide® Tablets 80 mg/5 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2006-08
    Completion
    2006-08
    Enrolment
    42

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionNadolol/Bendroflumethiazide Tablets 80 mg/5 mg; Corzide® Tablets 80 mg/5 mg
    PhasePhase 1
    Registry statusCompleted

  • Fasting Study of Nadolol/Bendroflumethiazide Tablets 80 mg/5 mg and Corzide® Tablets 80 mg/5 mg

    NCT00647660 · start 2006-07

    Registered record
    Registry ID
    NCT00647660
    Conditions
    Healthy
    Interventions
    Nadolol/Bendroflumethiazide Tablets 80 mg/5 mg; Corzide® Tablets 80 mg/5 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2006-07
    Completion
    2006-08
    Enrolment
    66

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionNadolol/Bendroflumethiazide Tablets 80 mg/5 mg; Corzide® Tablets 80 mg/5 mg
    PhasePhase 1
    Registry statusCompleted

  • Pathophysiological Mechanisms of Hypertensive LVH:Optimising Regression

    NCT00518479 · start 2003-09

    Registered record
    Registry ID
    NCT00518479
    Conditions
    Hypertension; Left Ventricular Hypertrophy
    Interventions
    Bendroflumethiazide 2.5mg OD; Amlodipine 10mg OD; Valsartan 160mg OD; Moxonidine 400mcg OD
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2003-09
    Completion
    2004-04
    Enrolment
    42

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension; Left Ventricular Hypertrophy
    InterventionBendroflumethiazide 2.5mg OD; Amlodipine 10mg OD; Valsartan 160mg OD; Moxonidine 400mcg OD
    PhaseNot applicable
    Registry statusCompleted

  • A Randomised, Parallel-group, Double-blind, Double-dummy Study to Compare the Effects of Lacidipine Versus Bendrofluazide on Markers of Platelet Activation and Haemorheological Factors in Hypertensive Patients

    NCT02235402 · start 1997-12

    Registered record
    Registry ID
    NCT02235402
    Conditions
    Hypertension
    Interventions
    Lacidipine; Bendrofluazide; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    1997-12
    Completion
    Not recorded
    Enrolment
    26

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    InterventionLacidipine; Bendrofluazide; Placebo
    PhasePhase 4
    Registry statusCompleted